November 22, 2023

 

VIA EDGAR

 

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Jane Park

 

  Re: bioAffinity Technologies, Inc.  
    Registration Statement on Form S-3  
   

Filed November 16, 2023

File No: 333-275608

 

 

Dear Ms. Park:

 

bioAffinity Technologies, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-275608), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Monday, November 27, 2023, at 4:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.

 

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

 

The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

 

  Very truly yours,
     
  BIOAFFINITY TECHNOGIES, INC.
     
  By: /s/ Maria Zannes
  Name: Maria Zannes
  Title: Chief Executive Officer

 

cc: Leslie Marlow, Blank Rome LLP